Phaseline

Companies › mAbxience Research

mAbxience Research: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 3 Phase 3; Oncology, Immunology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MB11
PD-1 inhibitor (nivolumab biosimilar)
PDCD1Phase 3Advanced (Unresectable or Metastatic) MelanomaApr 2027
MB12
PD-1 inhibitor
PDCD1Phase 3Non Squamous Non Small Cell Lung CancerSep 2027
MB04
TNF-alpha inhibitor
TNFPhase 3Rheumatoid Arthritis (RA)–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06596772MB04Phase 3Rheumatoid Arthritis (RA)ImmunologyFeb 2026
NCT07221734MB11Phase 3Advanced (Unresectable or Metastatic) MelanomaOncologyApr 2027
NCT06687369MB12Phase 3Non Squamous Non Small Cell Lung CancerOncologySep 2027

Targets

PDCD1 (2) TNF (1)

Companies with the same targets

Akeso Sichuan Baili Pharmaceutical Innovent Biologics (Suzhou) Shanghai Henlius Biotech Johnson & Johnson (Janssen) AstraZeneca Shenyang Sunshine Pharmaceutical Regeneron Pharmaceuticals Ono Pharmaceutical Mabwell (Shanghai) Bioscience

Companies built like this

Lepu Biopharma BriaCell Therapeutics Innovent Biopharmaceutical Technology (Hangzhou) Taizhou Hanzhong biomedical Maia Biotechnology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.